Fundraising Fox

Amgen

NASDAQ: AMGN

Thousand Oaks, US · Delaware corporation · 3 known investors

Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.

AI & Machine LearningBiotech

Founders & leadership

KN
Kave NiksefatinFounder
DP
David PiacquadNamed on SEC filing
FD
Francois de CarbonnelNamed on SEC filing
BM
Brian M. McNameeNamed on SEC filing
TJ
Tyler JacksNamed on SEC filing
RD
Ronald D. SugarNamed on SEC filing
RA
Robert A. BradwayNamed on SEC filing
DJ
David J. ScottNamed on SEC filing
MB
Madhavan BalachandranNamed on SEC filing
SA
Stuart A. TrossNamed on SEC filing
DW
David W. MelineNamed on SEC filing
SE
Sean E. HarperNamed on SEC filing

Investors · 3

Asset Management CompanyMenlo Park · $500K – $2M
Mayfield FundCupertino · $500K – $12M
Sunstone CapitalreportedFrederiksberg

Reported raises · per SEC filings

Form D private placements
▶$2.5BofferedJan 2015 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David PiacquadExecutive Officer
  • Francois de CarbonnelDirector
  • Brian M. McNameeExecutive Officer
  • Tyler JacksDirector
  • Ronald D. SugarDirector
  • Robert A. BradwayExecutive Officer, Director
  • David J. ScottExecutive Officer
  • Madhavan BalachandranExecutive Officer
  • Stuart A. TrossExecutive Officer
  • David W. MelineExecutive Officer
  • Sean E. HarperExecutive Officer
  • Rebecca M. HendersonDirector
  • Judith PelhamDirector
  • Vance D. CoffmanDirector
  • David BaltimoreDirector
  • Cynthia M. PattonExecutive Officer
  • Greg C. GarlandDirector
  • Frank C. HerringerDirector
  • Frank J. Biondi, Jr.Director
  • Robert A. EckertDirector
  • Anthony C. HooperExecutive Officer
  • R. Sanders WilliamsDirector
Offering amount
$2.5B
Minimum investment
$250K
Sales commissions
$750K
Placement agents
Deutsche Bank Securities Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Banc of America Securities LLC, Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated
First sale
Sep 2011
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Amgen is at 52-week highs; is there more upside By Investing.cominvesting.com · Sep 2026Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced?finance.yahoo.com · Aug 2026Incyte: Cheaper, Growing Faster, And The Market Keeps Paying Up For Amgen | Trefistrefis.com · Aug 2026Cantor Fitzgerald raises Amgen stock price target on core portfolio strength By Investing.cominvesting.com · Aug 2026TD Cowen raises Amgen stock price target on strong earnings beat By Investing.cominvesting.com · Aug 2026Qzqz.com · Aug 2026

Frequently asked questions

What does Amgen do?
Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Who are Amgen's investors?
Amgen's investors include Asset Management Company, Mayfield Fund, Sunstone Capital.
Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, US.